1. , , , et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1406–14.
2. , , eds. Efficacy of transdermal methylphenidate with reference to Concerta in ADHD. 52nd Annual Meeting of American Academy of Child and Adolescent Psychiatry; 2005 October 18–23; Toronto, Canada; 2005.
3. , , , et al. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(5):548–56.
4. , , , et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):700–8.
5. , Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–18.
6. , Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol. 1997;12:527–46.
7. , , , et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry. 1982;21(1):19–26.
8. , Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?J Clin Psychopharmacol. 2008;28(3):S54–61.
9. , , , et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241–8.
10. , , , et al. Interactions of attention-deficity/hyperactivity disorder therapy agents with the efflux transporter P-glycoprotein. Eur J Pharmacol. 2008;578:148–58.
11. , , , et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S–49S.
12. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology. 2007;191:5–13.
13. , , Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry. 1987;22:1357–68.
14. , How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?Aust N Z J Psychiatry. 2000;34:645–50.
15. , , , et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–35.
16. , , , , Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol. 2010;20(1):49–54.
17. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
18. , , , , ADHD treatment with a once-daily formulation of methylphenidate hydrochloride: a two-year study. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA; 2003.
19. , , , et al. Findings from the NIMH multimodal treatment study of ADHD: implications and applications for the primary care providers. J Dev Behav Pediatr. 2001;22:60–73.
20. . A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD [see comments]. Arch Gen Psychiatry. 1999;56(12):1073–86.
21. , , , Psychopharmacology in the medical setting. In: , , eds. Massachusetts General Hospital Handbook of General Hospital Psychiatry. Amsterdam: Elsevier Science Publishers. 2010; 441–66.
22. , , , et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32.
23. , , . Pharmacotherapy of ADHD: A life span perspective. In: , , eds. American Psychiatric Press Review of Psychiatry. Washington, DC: American Psychiatric Association. 1997; 87–128.
24. , , , Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006;8(4):4.
25. , , , Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol. 1998;20(5):617–27.
26. , , , , , Outcome results from the NIMH multi-site Preschool ADHD Treatment Study (PATS). 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2004 October 19–24; Washington, DC; 2004.
27. Treatment and assessment of ADHD in children and adolescents. In: , ed. ADHD Across the Lifespan: An Evidence-Based Understanding from Research to Clinical Practice. Hasbrouck Heights, NJ: Veritas Institute for Medical Education. 2006; 176–206.
28. , , , et al. Multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82–90.
29. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs. 2001;10(11):2003–11.
30. , , , Comparative effects of methylphenidate on ADD girls and boys. J Am Acad Child Adolesc Psychiatry. 1989;28(5):773–6.
31. , , Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559–67.
32. , , , et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.
33. , , , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–27.
34. , . Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003;39:180–5.
35. . National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–9.
36. , . Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003;16(5):711–18.
37. , , , et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–13.
38. , , , et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35(11):1460–9.
39. , , , Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.
40. , . Pediatric psychopharmacology update: psychostimulants and tics – past, present, and future. J Can Acad Child Adolesc Psychiatry. 2006;15(2):84–6.
41. , . Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficity hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999;38(8):944–51.
42. , , , , Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14(2):185–94.
43. , , , A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics. 2002;110(2):258–66.
44. , , , et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883–92.
45. , , , , Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56:330–6.
46. . Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527–36.
47. , , Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics. 1999;103(4):730–7.
48. , , , Stimulants and sudden death: what is a physician to do?Pediatrics. 2006;118(3):1215–19.
49. . Communication about an ongoing safety review of stimulant medication used in children with attention-deficit/hyperactivity disorder (ADHD). In: FDA US, ed.; 2009.
51. . Is suicidality serious? Curr Drug Saf. 2009;4(2):95–6.
52. , , Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451–3.
53. , , , et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;120(7):e55–9.
54. , , , , Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pedatrics. 2009;123:611–16.
55. , , , et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005;230(2):284–91.
56. , Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology. 1995;103:77–84.
57. , , Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49(20):5736–47.
58. . NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate. NIH Publication No. 05–4473; 2005.
59. , , , et al. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res. 2009;666(1–2):44–9.
60. , , , Does stimulant therapy of ADHD beget later substance abuse: a meta-analytic review of the literature. Pediatrics. 2003;11(1):179–85.
61. , , , et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764–76.
62. , , , et al. Effect of prior stimulant treatment for attention-deficit hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916–21.
63. , , , et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597–603.
64. , , , et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604–9.
65. , , , et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31.
66. , , , , . Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408–14.
67. , , , Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;99(1):96–106.
68. , , , , Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26(10):1501–10.
69. , , The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–116.
70. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007;102(5):740–51.
71. , , , et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792–8.
72. , , , . Implications of early versus late onset of attention-deficit/hyperactivity disorder symptoms. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1512–19.
73. , , Pharmacologic treatment of pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2003;18:455–69.
74. , . Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009;18(2):291–319, vii–viii.
75. , , , et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34:867–76.
76. , , , Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162:58–64.
77. , , , et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1445–53.
78. , , , et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord. 2001;3(2):53–7.
79. , , , et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283–94.
80. , , Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245–55.
81. . Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–74.
82. , , , et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538–44.
83. , , , , . A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49–56.
84. , , A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003;45:292–5.
85. , , , et al. The frequency, complications, and aetiology of ADHD in new onset paediatric epilepsy. Brain. 2007;130:3135–48.
86. , , , et al. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs. 2008;17(1):77–84.
87. , , , , . The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims data. Curr Drug Saf. 2008;3(2):123–31.
88. , , , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010;18(3):229–37.
89. , , , . Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?J Child Adolesc Psychopharmacol. 2008;18(3):257–64.
90. , , , , Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71–8.